| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RNASET2 |
| Uniprot No | O00584 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-256aa |
| 氨基酸序列 | DKRLRDNHEWKKLIMVQHWPETVCEKIQNDCRDPPDYWTIHGLWPDKSEGCNRSWPFNLEEIKDLLPEMRAYWPDVIHSFPNRSRFWKHEWEKHGTCAAQVDALNSQKKYFGRSLELYRELDLNSVLLKLGIKPSINYYQVADFKDALARVYGVIPKIQCLPPSQDEEVQTIGQIELCLTKQDQQLQNCTEPGEQPSPKQEVWLANGAAESRGLRVCEDGPVFYPPPKKTKH |
| 预测分子量 | 56.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RNASET2重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**：*RNASET2 Acts as a Tumor Suppressor by Promoting M1 Macrophage Polarization in Breast Cancer Microenvironments*
**作者**：Sangaletti S. et al.
**摘要**：该研究通过重组RNASET2蛋白处理乳腺癌模型，发现其通过激活TLR4/NF-κB通路诱导巨噬细胞向M1型极化，抑制肿瘤生长并改善免疫微环境。
2. **文献名称**：*Recombinant Human RNASET2 Inhibits Ovarian Cancer Progression by Disrupting Extracellular Matrix*
**作者**：Shah R. et al.
**摘要**：体外实验表明，重组RNASET2通过降解肿瘤细胞外基质(ECM)中的核糖核酸成分，抑制卵巢癌细胞迁移和侵袭，提示其作为潜在抗转移治疗分子。
3. **文献名称**：*Expression and Functional Characterization of RNASET2 in a Prokaryotic System*
**作者**：Mohan A. et al.
**摘要**：研究优化了RNASET2重组蛋白在大肠杆菌中的可溶性表达及纯化工艺，并验证其核糖核酸酶活性，为后续功能研究提供了高效制备方法。
---
以上文献涵盖RNASET2在肿瘤免疫调控、转移抑制及重组表达技术方面的关键进展，可作为研究基础参考。如需具体期刊信息或DOI号，可进一步补充检索。
**Background of RNASET2 Recombinant Protein**
RNASET2. a member of the ribonuclease T2 (RNASE) family, is a conserved glycoprotein involved in diverse biological processes, including RNA metabolism, immune regulation, and cellular homeostasis. It is encoded by the *RNASET2* gene, which is evolutionarily conserved across eukaryotes. The protein exhibits ribonuclease activity, preferentially cleaving single-stranded RNA, and is implicated in lysosomal function, where it contributes to RNA degradation and nutrient recycling.
Recombinant RNASET2 is produced using biotechnological platforms, such as *E. coli*, yeast, or mammalian expression systems, to generate purified protein for research and therapeutic applications. Its recombinant form often retains enzymatic activity and structural integrity, enabling studies on its molecular mechanisms. Structurally, RNASET2 contains a conserved RNASE domain and undergoes post-translational modifications, such as glycosylation, which may influence its stability and function.
Research highlights RNASET2's role in pathological contexts. It acts as a tumor suppressor in certain cancers by inhibiting angiogenesis and modulating the tumor microenvironment. Additionally, RNASET2 dysregulation is linked to autoimmune disorders, neurodegenerative diseases, and rare genetic conditions like cystic leukoencephalopathy. Its ability to interact with immune cells, such as macrophages, underscores its potential in regulating inflammation and innate immunity.
The recombinant protein serves as a valuable tool for elucidating RNASET2's signaling pathways, including its crosstalk with pathways like TGF-β and NF-κB. It also holds therapeutic promise; preclinical studies explore its use in anti-cancer therapies or as a biomarker for disease progression. Challenges remain in optimizing its stability, delivery, and specificity for clinical translation. Overall, RNASET2 recombinant protein bridges fundamental research and applied medicine, offering insights into its multifunctional roles and therapeutic potential.
(Word count: 249)
×
